Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nara Biosciences has completed an agreement with Boston University to license the MyoMouse discovery platform. The exclusive license includes all commercial rights to novel therapeutic factors discovered using the MyoMouse.
Subscribe to our email newsletter
The newly licensed myokines include a novel secreted protein named NK102 which has demonstrated significant blood glucose reductions when administered to obese animals. Other licensed proteins include NK110 which has demonstrated muscle protection and repair in models of muscle injury and NK111 which has demonstrated cardioprotective effects in animal models of cardiac ischemia.
Jon Alsenas, chief business officer of Nara, said: “Since exercise, particularly weight training, is difficult if not impossible for many patients to perform regularly, the administration of these newly discovered myokines offers the possibility of providing to the population at large many of the health benefits enjoyed by those who are physically trained.”